Determinants associated with 2 to 5 quality indicators were extranodal involvement, MTC, DLBCL tumor type, tumor aggressiveness, LDH and Hb level, therapy used and hospital region. The gene discussed is GSTM1; the disease is medullary thyroid gland carcinoma.